EFDA Maturity Level 3 and Local Manufacturing Incentives in Ethiopia

1. Key takeaways

The regulatory variables in Ethiopia have shifted materially over the past two years: in September 2025 EFDA reached World Health Organization (WHO) regulatory maturity level 3 (ML3) for medicines, becoming the ninth on the African continent and the first in the Intergovernmental Authority on Development (IGAD) region; in the same period, the share of local production in the domestic market rose from 8% to 44% (as stated by the Minister of Health at the 76th session of the WHO Regional Committee for Africa), and a World Bank feature described the shift by noting that local production now exceeds 40% of the medicines supply. For medical device manufacturers, the direct meaning of ML3 is not softer review: it is improved regulatory predictability combined with rising localization substitution pressure, arriving at the same time. Both forces reshape market-entry economics, and neither excuses a company from the ordinary requirements of authorization, import permits and local representation.

2. Legal basis

3. Expert insights

Insight 1: ML3 was assessed for medicines; devices have not yet completed an equivalent assessment.

Both the World Bank and EFDA formulations point to medicines regulation reaching ML3. What EFDA launched on July 28, 2026 is a self-assessment of the medical device system (WHO GBT+ medical devices module), which remains at the self-assessment stage and has not yet produced a public maturity conclusion equivalent to the medicines result. Equating ML3 directly with devices-regulation-at-ML3 is the most common information error circulating about this market. Communications, tender documents and internal justifications should keep the two assessments strictly separate, because a misstatement can surface later in diligence.

Insight 2: The GBT assesses the system, not individual products.

The WHO Global Benchmarking Tool (GBT) covers the complete regulatory cycle from approval, inspection and quality control testing to post-market surveillance and governance, through more than 250 indicators. What ML3 delivers is therefore procedural certainty (clear nodes, predictable timelines, traceable decisions), not lower technical requirements. For companies already operating in other African ML3 markets, the practical value lies in analogous review pathways: the structural expectations of the authority can be anticipated, but the evidence demands for each device remain fully in force.

Insight 3: Localization substitution is industrial policy and will squeeze import shares.

The rise in local production share from 8% to 44% shows that import substitution in Ethiopia is an executed policy outcome, not a slogan. The direct consequence for device manufacturers is that the bargaining space for a pure-import model narrows on the public procurement side, and options such as local assembly, local partnership or technology transfer need to be evaluated. (Practical estimate: some public reporting indicates that a 2025 directive of the Ministry of Finance restricted public procurers from international tendering for products that local manufacturers can supply; the original official text could not be obtained, and this is not cited as a confirmed conclusion.)

Insight 4: The Kilinto park offers a platform, not an exemption.

The World Bank feature notes that the Kilinto special economic zone has built dedicated manufacturing parks for pharmaceuticals and medical equipment. Settling in the park solves land, infrastructure and approval-coordination problems; the products themselves must still complete EFDA’s market authorization and import permit procedures. A factory address in a special zone changes none of the product-level obligations, and treating the park as a regulatory shortcut is a planning error.

Insight 5: Regional recognition is forming an ML3 club.

In the World Bank feature, the Director General of EFDA mentions that 8 countries that have reached ML3 have signed agreements to mutually recognize one another’s decisions. This offers device manufacturers a potential path of leveraging one national approval into multi-country access, but the maturity of mutual-recognition mechanisms in the device field is significantly lower than for medicines, and at the current stage companies should still file country by country, treating recognition as a medium-term variable rather than a near-term lever.

4. Practical recommendations

1. Use ML3 as a process-expectation management tool: prepare materials against the full regulatory cycle covered by the GBT, with emphasis on strengthening post-market surveillance and vigilance systems.
2. Keep the medicines and devices maturity statuses distinct: never state in external communications that devices have reached ML3.
3. Assess localization feasibility: for high-volume, low-unit-price, freight-heavy categories, model local assembly or local partnership options.
4. Track the device self-assessment outcome: the formal assessment conclusions that follow the self-assessment will directly affect review requirements and how far reliance pathways open.
5. Do not bet on mutual recognition: schedule submissions country by country at this stage and treat regional recognition as a medium-term variable.
6. Re-check policy sources before citing: localization policy moves frequently, and any figure used in a business case should be traced to the official original text.

5. Verification checklist

• □ Confirmed that ML3 applies to medicines regulation
• □ Recorded the ML3 achievement date: September 2025 (ninth in Africa, first in IGAD)
• □ Tracking progress of the device system self-assessment launched on July 28, 2026
• □ Feasibility of local production or partnership has been assessed
• □ System documentation aligned with the WHO GBT framework of more than 250 indicators
• □ External materials do not claim that devices have reached ML3
• □ Submissions scheduled country by country, without relying on regional recognition

Regulatory information verified as of October 29, 2026. The ML3 outcome, local production share and self-assessment launch date listed in this article are governed by the EFDA official announcement, the public statements of the Ethiopian Ministry of Health and the World Bank feature as currently published; localization-related policies change frequently, and the official original texts must be checked before citation.

Local resource in Ethiopia: GRZAN supports manufacturers from the Chinese mainland and overseas in engaging with the Ethiopian Food and Drug Authority (EFDA) on market authorization (MA), Certificate of Competence (CoC) and import permit applications, including local agent structuring and agency agreement review, SRA reliance pathway justification, UMDN coding and classification determination, technical documentation preparation, and the establishment of vigilance and post-market surveillance systems. Service capabilities cover product attribute determination and risk classification (non-IVD Class I–IV / IVD Class A–D), market authorization applications and re-registration, applicability assessment for the low-risk notification procedure, Essential Principles conformity reasoning, label and instruction-for-use localization in English, and vigilance reporting with field safety corrective action support. Contact: hito.lin@grzan.cn; website www.grzan.cn. For market-entry strategy, localization assessment and local authorized representative support in the Ethiopian market, GRZAN can also be reached at info@grzanglobal.com.